Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.

HPV genotype HPV vaccine Luminex assay epidemiological monitoring human papillomavirus multiple infections urine sample

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
04 09 2022
Historique:
received: 26 06 2020
accepted: 11 11 2020
pubmed: 19 11 2020
medline: 9 9 2022
entrez: 18 11 2020
Statut: ppublish

Résumé

Whether type-specific human papillomavirus (HPV) infection influences the risk of acquiring infections with other HPV types is unclear. We studied concurrent HPV infections in 17-year-old girls from 2 birth cohorts; the first vaccine-eligible cohort in Norway and a prevaccination cohort. Urine samples were collected and tested for 37 HPV genotypes. This study was restricted to unvaccinated girls from the prevaccination cohort (n = 5245) and vaccinated girls from the vaccine-eligible cohort (n = 4904). Risk of HPV infection was modelled using mixed-effect logistic regression. Expected frequencies of concurrent infection with each pairwise combination of the vaccine types and high-risk types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) were compared to observed frequencies. Infection with multiple HPV types was more common among unvaccinated girls than vaccinated girls (9.2% vs 3.7%). HPV33 and HPV51 was the only HPV pair that was detected together more often than expected among both unvaccinated (P = .002) and vaccinated girls (P < .001). No HPV pairs were observed significantly less often than expected. HPV33 and HPV51 tended to be involved in coinfection among both unvaccinated and vaccinated girls. The introduction of HPV vaccination does not seem to have had an effect on the tendency of specific HPV types to cluster together.

Sections du résumé

BACKGROUND
Whether type-specific human papillomavirus (HPV) infection influences the risk of acquiring infections with other HPV types is unclear. We studied concurrent HPV infections in 17-year-old girls from 2 birth cohorts; the first vaccine-eligible cohort in Norway and a prevaccination cohort.
METHODS
Urine samples were collected and tested for 37 HPV genotypes. This study was restricted to unvaccinated girls from the prevaccination cohort (n = 5245) and vaccinated girls from the vaccine-eligible cohort (n = 4904). Risk of HPV infection was modelled using mixed-effect logistic regression. Expected frequencies of concurrent infection with each pairwise combination of the vaccine types and high-risk types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) were compared to observed frequencies.
RESULTS
Infection with multiple HPV types was more common among unvaccinated girls than vaccinated girls (9.2% vs 3.7%). HPV33 and HPV51 was the only HPV pair that was detected together more often than expected among both unvaccinated (P = .002) and vaccinated girls (P < .001). No HPV pairs were observed significantly less often than expected.
CONCLUSIONS
HPV33 and HPV51 tended to be involved in coinfection among both unvaccinated and vaccinated girls. The introduction of HPV vaccination does not seem to have had an effect on the tendency of specific HPV types to cluster together.

Identifiants

pubmed: 33205203
pii: 5986714
doi: 10.1093/infdis/jiaa709
pmc: PMC9441200
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-633

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2439-45
pubmed: 16214929
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
J Infect Dis. 2011 Aug 1;204(3):385-90
pubmed: 21742837
Am J Epidemiol. 2014 Dec 1;180(11):1066-75
pubmed: 25355446
Am J Epidemiol. 2016 Dec 15;184(12):873-883
pubmed: 27927619
PLoS One. 2016 Dec 22;11(12):e0166329
pubmed: 28005904
Pediatrics. 2012 Nov;130(5):798-805
pubmed: 23071201
J Clin Microbiol. 2006 Feb;44(2):504-12
pubmed: 16455905
Papillomavirus Res. 2016 Dec;2:153-158
pubmed: 29074174
J Infect Chemother. 2016 Aug;22(8):559-62
pubmed: 27342077
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
J Med Virol. 2011 Nov;83(11):1983-7
pubmed: 21915874
J Infect Dis. 2018 Nov 5;218(12):1900-1910
pubmed: 30010913
APMIS. 2010 May;118(5):346-52
pubmed: 20477809
CMAJ. 2015 Feb 3;187(2):E74-E81
pubmed: 25487660
Epidemiology. 2018 Sep;29(5):666-674
pubmed: 29923864
J Infect Dis. 2011 Apr 1;203(7):910-20
pubmed: 21402543
J Infect Dis. 2012 Jan 1;205(1):72-81
pubmed: 22058418
Int J Cancer. 2018 Jun 15;142(12):2491-2500
pubmed: 29377141
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):503-10
pubmed: 20142247
Am J Epidemiol. 2013 Aug 15;178(4):625-34
pubmed: 23660798
PLoS One. 2013 Aug 19;8(8):e71617
pubmed: 23977090
J Infect Dis. 2011 Nov 15;204(10):1500-4
pubmed: 21908729
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Clin Microbiol Infect. 2015 Sep;21(9):808-16
pubmed: 26003284
Vaccine. 2014 Sep 3;32(39):4945-53
pubmed: 25045810
J Infect Dis. 2012 Oct;206(8):1291-8
pubmed: 22872732
Euro Surveill. 2012 Apr 19;17(16):
pubmed: 22551462
Nucleic Acids Res. 2017 Jan 4;45(D1):D499-D506
pubmed: 28053164
Acta Obstet Gynecol Scand. 2011 May;90(5):459-67
pubmed: 21306319
J Clin Microbiol. 2009 Mar;47(3):541-6
pubmed: 19144817
Emerg Infect Dis. 2016 Oct;22(10):1732-40
pubmed: 27648688
Virology. 2009 Feb 20;384(2):260-5
pubmed: 19135222
Bioinformatics. 2009 Aug 1;25(15):1972-3
pubmed: 19505945
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):159-69
pubmed: 20056635
Int J Cancer. 2013 Sep 15;133(6):1271-85
pubmed: 22961444
Am J Epidemiol. 2014 May 15;179(10):1236-46
pubmed: 24714726
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
J Infect Dis. 2011 Apr 1;203(7):891-3
pubmed: 21402540
Eur J Cancer. 2012 Jul;48(11):1633-7
pubmed: 22088483
BMJ. 2014 Sep 16;349:g5264
pubmed: 25232064
Vaccine. 2013 Mar 15;31(12):1604-9
pubmed: 23313651

Auteurs

Ida Laake (I)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Berit Feiring (B)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Christine Monceyron Jonassen (CM)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.

John H O Pettersson (JHO)

Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, University of Sydney, Sydney, Australia.

Torstein Gjølgali Frengen (TG)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Ingerid Ørjansen Kirkeleite (IØ)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Lill Trogstad (L)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH